NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech), (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/982,610, a patent that claims the use of an ophthalmic solution comprising cannabinoids for the treatment of glaucoma and symptomatic relief of conjunctival inflammation. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from AXIM’s patent application, 14/982,610, filed in December 2015.
AXIM® Biotech announced on March 21, 2017 that it retained the services of Ora®, Inc., a global Contract Research Organization (“CRO”), to perform the company’s product development (based on AXIM’s IP) in glaucoma and dry eye syndrome utilizing cannabinoid-based therapeutics through its AX-1603 and
... read more at: https://globenewswire.com/news-release/2017/10/05/1141427/0/en/New-U-S-Patent-Allowance-Granted-to-AXIM-Biotechnologies-Inc-for-Cannabinoid-Ophthalmic-Solutions-for-Glaucoma-and-Conjunctivitis-Treatment.html